523 related articles for article (PubMed ID: 25529082)
21. Triple therapy with boceprevir or telaprevir for prior HCV non-responders.
Asselah T
Best Pract Res Clin Gastroenterol; 2012 Aug; 26(4):455-62. PubMed ID: 23199504
[TBL] [Abstract][Full Text] [Related]
22. Emerging treatments for hepatitis C.
Flisiak R; Jaroszewicz J; Parfieniuk-Kowerda A
Expert Opin Emerg Drugs; 2013 Dec; 18(4):461-75. PubMed ID: 24102413
[TBL] [Abstract][Full Text] [Related]
23. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals.
Hagan LM; Sulkowski MS; Schinazi RF
Hepatology; 2014 Jul; 60(1):37-45. PubMed ID: 24677184
[TBL] [Abstract][Full Text] [Related]
24. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
Laguno M; Von Wichmann MA; Van den Eynde E; Navarro J; Cifuentes C; Murillas J; Veloso S; Martínez-Rebollar M; Guardiola JM; Jou A; Gómez-Sirvent JL; Cervantes M; Pineda JA; López-Calvo S; Carrero A; Montes ML; Deig E; Tapiz A; Ruiz-Mesa JD; Cruceta A; de Lazzari E; Mallolas J
Int J Infect Dis; 2016 Dec; 53():46-51. PubMed ID: 27815225
[TBL] [Abstract][Full Text] [Related]
25. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.
Chayama K; Takahashi S; Toyota J; Karino Y; Ikeda K; Ishikawa H; Watanabe H; McPhee F; Hughes E; Kumada H
Hepatology; 2012 Mar; 55(3):742-8. PubMed ID: 21987462
[TBL] [Abstract][Full Text] [Related]
26. Antiviral strategies in hepatitis C virus infection.
Sarrazin C; Hézode C; Zeuzem S; Pawlotsky JM
J Hepatol; 2012; 56 Suppl 1():S88-100. PubMed ID: 22300469
[TBL] [Abstract][Full Text] [Related]
27. Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?
Pascale A; Serfaty L
J Hepatol; 2013 Feb; 58(2):391-4. PubMed ID: 23063419
[TBL] [Abstract][Full Text] [Related]
28. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial.
Forns X; Lawitz E; Zeuzem S; Gane E; Bronowicki JP; Andreone P; Horban A; Brown A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; Scott J; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
Gastroenterology; 2014 Jun; 146(7):1669-79.e3. PubMed ID: 24602923
[TBL] [Abstract][Full Text] [Related]
29. Interferon free therapy with direct acting antivirals for HCV.
Asselah T; Marcellin P
Liver Int; 2013 Feb; 33 Suppl 1():93-104. PubMed ID: 23286852
[TBL] [Abstract][Full Text] [Related]
30. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
[TBL] [Abstract][Full Text] [Related]
31. Simeprevir for the treatment of chronic hepatitis C genotype 1 infection.
Takehara T
Expert Rev Anti Infect Ther; 2014 Aug; 12(8):909-17. PubMed ID: 24882512
[TBL] [Abstract][Full Text] [Related]
32. What's new in HCV genotype 2 treatment.
Mangia A; Mottola L
Liver Int; 2012 Feb; 32 Suppl 1():135-40. PubMed ID: 22212584
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review.
Yau AH; Yoshida EM
Can J Gastroenterol Hepatol; 2014 Sep; 28(8):445-51. PubMed ID: 25229466
[TBL] [Abstract][Full Text] [Related]
34. Emerging therapies for hepatitis C.
Kim DY; Ahn SH; Han KH
Gut Liver; 2014 Sep; 8(5):471-9. PubMed ID: 25228970
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
Najafzadeh M; Andersson K; Shrank WH; Krumme AA; Matlin OS; Brennan T; Avorn J; Choudhry NK
Ann Intern Med; 2015 Mar; 162(6):407-19. PubMed ID: 25775313
[TBL] [Abstract][Full Text] [Related]
36. Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C.
Satsangi S; Mehta M; Duseja A; Taneja S; Dhiman RK; Chawla Y
J Gastroenterol Hepatol; 2017 Apr; 32(4):859-863. PubMed ID: 27624314
[TBL] [Abstract][Full Text] [Related]
37. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
Manns MP; Markova AA; Calle Serrano B; Cornberg M
Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
[TBL] [Abstract][Full Text] [Related]
38. Two patients treated with simeprevir plus pegylated-interferon and ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation: case report.
Kawaoka T; Imamura M; Kan H; Fujino H; Fukuhara T; Kobayashi T; Honda Y; Naeshiro N; Hiramatsu A; Tsuge M; Hayes CN; Kawakami Y; Aikata H; Ochi H; Ishiyama K; Tashiro H; Ohdan H; Chayama K
Transplant Proc; 2015 Apr; 47(3):809-14. PubMed ID: 25891736
[TBL] [Abstract][Full Text] [Related]
39. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
[TBL] [Abstract][Full Text] [Related]
40. Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.
Fraser I; Burger J; Lubbe M; Dranitsaris G; Sonderup M; Stander T
Pharmacoeconomics; 2016 Apr; 34(4):403-17. PubMed ID: 26666639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]